# Sahajanand Medical Technologies Receives DGGI Summons Over Clinical Trial GST Compliance

> Sahajanand Medical Technologies received a DGGI summons on October 23, 2026, over GST compliance on clinical trial reimbursements to foreign subsidiaries.

- Published: 2026-10-24T07:49:19+00:00
- Section: Regulation & Approvals
- Author: News Desk
- URL: https://newsforagent.com/news/2026-10-24/sahajanand-medical-dggi-gst-summons
- Source: [ScanX](https://scanx.trade/stock-market-news/companies/sahajanand-medical-technologies-receives-dggi-summons-gst-inquiry/54369561)

## Key takeaways

- Sahajanand Medical Technologies received a DGGI summons dated October 16, 2026, on October 23, 2026, over GST compliance on reimbursements to foreign subsidiaries for clinical trials.
- The company said the summons has no material financial impact at this stage and that it is fully cooperating with authorities.
- Sahajanand Medical Technologies appointed Deepshikha Singhal as Company Secretary and Compliance Officer, effective April 1, 2025, following board approval on April 16, 2025.

[Sahajanand Medical Technologies](https://akta.pro/company-profiles/0000uu1/sahajanand-medical-technologies) has received a summons from the Directorate General of GST Intelligence (DGGI) over GST compliance on re-imbursements to foreign subsidiaries for clinical trials, the company said. [ScanX](https://scanx.trade/stock-market-news/companies/sahajanand-medical-technologies-receives-dggi-summons-gst-inquiry/54369561) reported that the summons, dated October 16, 2026, was received by the company on October 23, 2026.

## The DGGI Summons and Its Scope

The summons was issued by the Zonal Unit in Mumbai under Section 70 of the Central Goods and Services Tax Act, 2017, to the company's GSTIN. The authority involved is the Superintendent or Senior Intelligence Officer of the DGGI Branch, Zonal Unit Mumbai. The inquiry concerns verification of books of accounts for GST compliance on clinical trial reimbursements.

The company stated that it is fully cooperating with the authorities and will provide all necessary information as required. Management asserted that the summons does not have any material financial impact on the company at this stage. The specific violations alleged are not detailed in the summons, which primarily calls for evidence regarding the specified transactions. Sahajanand Medical Technologies will keep the stock exchanges informed of further significant developments, if any. The disclosure was made to stock exchanges pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and includes details required as per SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024.

## Sahajanand Medical Technologies at a Glance

Sahajanand Medical Technologies is an India-based medical device company that develops and manufactures minimally invasive cardiovascular devices, including coronary drug-eluting stents, PTCA balloons, TAVI systems, and occluders, according to akta.pro [company records](https://akta.pro/company-data). The company serves hospitals and interventional cardiologists across more than 75 countries. It was founded in 2001 and is headquartered in Surat. Its revenue estimate is $100 million-$250 million, and its valuation estimate is $500 million-$1 billion. Total funding stands at $61.3 million, with the last round on January 9, 2023. The company has three funding rounds on record, including a 2018-01 private equity round of $36.1 million led by Morgan Stanley and Samara Capital, and a 2016-12 private equity round of $25.2 million led by Samara Capital.

## Earlier Sahajanand Medical Technologies Developments

Sahajanand Medical Technologies appointed Deepshikha Singhal as Company Secretary and Compliance Officer, effective April 1, 2025, following board approval on April 16, 2025, ScanX reported in October 2026. In September 2026, the company received EU MDR certification for its Supraflex Cruz sirolimus-eluting stent and product family, Ani News reported. Also in September 2026, it received regulatory approval from Egypt's EDA for its Supraflex Cruz sirolimus-eluting stent, enabling market entry in Africa, The Tribune reported.

## What Comes Next for Sahajanand Medical Technologies

Sahajanand Medical Technologies will keep the stock exchanges informed of further significant developments, if any, regarding the DGGI summons. The company is preparing for an initial public offer of equity shares, with SEBI approving its IPO proposal in November 2025, according to the same records.

## Companies in this story

- [Sahajanand Medical Technologies company profile](https://akta.pro/company-profiles/0000uu1/sahajanand-medical-technologies) · website: http://www.smtpl.com

---
News for Agent · https://newsforagent.com/llms.txt